Frontlight ResearchEarly access
TerminatedPhase 2
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 4 people enrolled
- Started
- 1 Dec 2020
- Ended
- 5 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Hyperpolarized 13C-Pyruvate
- Record updated
- 15 July 2026
- Why it stopped
- "Study terminated due to institutional resource constraints, including limited availability of specialized equipment and technical support. Termination was not related to participant safety, data quality, study conduct, or the investigational product
Who can take part
- Age
- 40 years to 80 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (5)Hide the full registry criteria
Who can take part
- Age greater than 40 and less than 80 years
- Clinical suspicion or history of prostate cancer reflected by one of the following:; PSA > 4ng/ml; Abnormal DRE exam; Known tissue diagnosis of prostate cancer from prior workup
- Patient planning to undergo either a MRI targeted biopsy or radical prostatectomy for prostate cancer workup or treatment
Who cannot take part
- Inability to undergo MRI scan
- Inability to receive IV contrast as per institutional protocol
Where in United States
- University of Maryland Medical CenterBaltimore, United States
About the trial
What the trial wants to find out
This is a two-tiered pilot study in which there will be no randomization and no placebo treatment. This study will be to perform metabolic magnetic resonance imaging on men suspected to have a prostate cancer to understand if metabolic MRI can be safely performed on this population
The group in the trial
- Single-arm study in patients who are suspected or known to have prostate cancerTreatment being tested
Perform metabolic magnetic resonance imaging on men suspected to have a prostate cancer to understand if metabolic MRI can be safely performed on this population
Treatment: Hyperpolarized 13C-Pyruvate
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging in the Diagnosis and Risk-Stratification of Prostate Cancer
- Record updated
- 15 July 2026